A Phase 4 interventional study of Bambuterol Hydrochloride tablets in Eosinophilic Bronchitis and Cough Variant Asthma, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-12-06.
Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Phase 4, Interventional, and Treatment
This study aim is to observe the response to Bambuterol Hydrochloride tablets treatment in subjects with eosinophilic bronchitis .
The investigators hypothesize:
A few of subjects with EB have some responses to Bambuterol Hydrochloride tablets therapy.
Most of subjects with CVA respond well to Bambuterol Hydrochloride tablets therapy
Study groups:
45 patients with chronic cough will be collected and two groups will formed based on diagnosis as follows:
Group 1: EB group The patients with eosinophilic bronchitis received Bambuterol Hydrochloride tablets 10mg Q24 for three days .
Group 2: CVA group The patients with cough variant asthma received Bambuterol Hydrochloride tablets 10mg Q24 for three days .
Observe the response to Bambuterol Hydrochloride tablets treatment three days later and compare the effective rate of patients with EB and CVA. Then the study will be over.
268 studies on the registry are indexed under Bronchitis; 26 are open to participants now.
This study's planned enrollment of 45 is below the median of 120 across 184 interventional studies indexed under Bronchitis.
Browse Bronchitis studies →The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 158 studies on the registry; 65 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
Drug: Bambuterol Hydrochloride tablets
Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
Drug: Bambuterol Hydrochloride tablets
Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
Day-time and night-time cough symptom total-score changes from baseline to day 3.
Time frame: three days
cough sensitivity from baseline to day 3
Time frame: three days
This study is status unknown, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Guangzhou Medical University